Transcode Therapeutics (RNAZ) Net Cash Flow (2020 - 2026)
Transcode Therapeutics' (RNAZ) quarterly Net Cash Flow came in at -$5.0 million in Q1 2026, down 186.83% YoY from $5.8 million in Q1 2025, and down 133.37% on a QoQ basis from $15.0 million in Q4 2025.
Transcode Therapeutics (RNAZ) Net Cash Flow (2020 - 2026) Analysis & Trends
Transcode Therapeutics (RNAZ) has 7 years of Net Cash Flow data on file, last reported at -$5.0 million in Q1 2026.
- Quarterly Net Cash Flow fell 186.83% year-over-year to -$5.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.2 million (down 81.24% YoY) and the FY2025 annual result came in at $12.0 million, up 294.37% from the prior year.
- Net Cash Flow retreated to -$5.0 million in Q1 2026, from $15.0 million in the prior quarter.
- In the past five years, Net Cash Flow ranged from a high of $15.0 million in Q4 2025 to a low of -$5.0 million in Q1 2026.
- A 5-year average of -$471053.1 and a median of -$3.3 million in 2023 frame the typical range for Net Cash Flow.
- Annual changes were most pronounced in 2022 — Net Cash Flow plunged 17503.72% — and 2025, when it jumped 280.72%.
- Tracing RNAZ's Net Cash Flow over 5 years: stood at -$3.8 million in 2022, then dropped by 22.58% to -$4.7 million in 2023, then soared by 183.99% to $3.9 million in 2024, then jumped by 280.72% to $15.0 million in 2025, then sank by 133.37% to -$5.0 million in 2026.
- The last three Net Cash Flow figures came in at -$5.0 million (Q1 2026), $15.0 million (Q4 2025), and -$4.5 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.82 Bn | 131.97 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 86.69 Bn | 78.70 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 65.23 Bn | 60.05 Bn | 1.37 Bn | - |
| 4 | Moderna | 60.16 Bn | 55.02 Bn | 52.00 Mn | -183.00 Mn |
| 5 | BeOne Medicines | 42.16 Bn | 37.07 Bn | 1.53 Bn | 407.41 Mn |
| 6 | Alnylam Pharmaceuticals | 31.86 Bn | 28.55 Bn | 992.69 Mn | -496,000.00 |
| 7 | BioNTech SE | 28.24 Bn | 9.85 Bn | 668.28 Mn | -2.83 Bn |
| 8 | Insmed | 27.53 Bn | 26.37 Bn | 358.27 Mn | -37.14 Mn |
| 9 | Royalty Pharma | 27.31 Bn | 26.47 Bn | - | 225.59 Mn |
| 10 | Transcode Therapeutics | 2.82 Mn | 2.82 Mn | - | -5.40 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -5.00 Mn |
| Mar 31, 2026 | -5.00 Mn |
| Dec 31, 2025 | 14.98 Mn |
| Dec 31, 2025 | 14.98 Mn |
| Sep 30, 2025 | -4.54 Mn |
| Sep 30, 2025 | -4.54 Mn |
| Jun 30, 2025 | -4.19 Mn |
| Jun 30, 2025 | -4.19 Mn |
| Mar 31, 2025 | 5.76 Mn |
| Mar 31, 2025 | 5.76 Mn |
| Dec 31, 2024 | 3.94 Mn |
| Dec 31, 2024 | 3.94 Mn |
| Sep 30, 2024 | -1.48 Mn |
| Sep 30, 2024 | -1.48 Mn |
| Jun 30, 2024 | -1.56 Mn |
| Jun 30, 2024 | -1.56 Mn |
| Mar 31, 2024 | 2.15 Mn |
| Mar 31, 2024 | 2.15 Mn |
| Dec 31, 2023 | -4.69 Mn |
| Dec 31, 2023 | -4.69 Mn |